The UK Oncology Nursing Society (UKONS) Annual Conference 2017, held in Harrogate, UK, had the central theme of person-centered care.…
With the NHS being stretched considerably in terms of its budget and increasing pressure placed upon its staff, any strategies…
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses the affordability of cancer treatments at the 2017…
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses novel conceptual treatment approaches at the 2017 International…
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses the evolution of CAR T-cell therapy at the…
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses recent developments in BTK inhibitors at the 2017…
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses highlights of the 2017 International Workshop in Non-Hodgkin…
Michael Pfreundschuh, MD from the Saarland University, Homburg, Germany is joined by Ryan Morin, PhD from the BC Cancer Agency,…
Anas Younes, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY is joined by Eduardo Sotomayor, MD, from…
Catherine Bollard, MBChB, MD, FRACP, FRCPA from the Childrens National Health System and the George Washington University, Washington, D.C. chairs…
Philippe Gaulard, MD, PhD, from the Henri-Mondor Hospital, Paris, France, Francesco DAmore, MD, PhD, from the Aarhus University, Aarhus, Denmark,…
Patients with myeloproliferative neoplasm (MPNs) are at a higher risk of mortality due to thrombosis compared with unaffected individuals. Speaking…
In this interview, recorded at the Myeloma 2017 meeting in Edinburgh, UK, Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, from…
Around a quarter of new amyloidosis patients die within 6 months of diagnosis, and, despite large pharmacological and technological advancements,…
There are two primary routes of therapy for amyloidosis: treating the underlying plasma cell dyscrasia, and clearing amyloid deposits. In…
Key to the treatment of amyloidosis is being able to discern the severity of illness, so that the patient can…
Prostate cancer therapies have developed greatly in recent years, with many more options for treatment available that can provide patients…
A clinical nurse specialist plays a critical role in the treatment of a cancer patient. In this interview, Hilary Baker…
Nathan Fowler, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses side effects of PI3K inhibitors…
Idelalisib was the first phosphoinositide 3-kinase (PI3K) inhibitor to be used in lymphoma, which had remarkable responses on B-cell lymphomas…
Marek Trneny, MD, from the Charles University, Prague, Czech Republic, discusses highlights from the International Workshop on Non-Hodgkin Lymphoma (iwNHL)…
John Kuruvilla, MD, FRCPC, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses integrating treatments around autologous transplantation at the…
John Kuruvilla, MD, FRCPC, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses the development of IMiDs at the International…
The exciting field of proton beam therapy is still developing; thus, as its utilization in the UK increases there is…
The introduction of new healthcare tools requires the careful navigation of social, political and economic pressures. In this interview, recorded…
The uptake of proton beam therapy has been slower in the UK compared with other developed countries; however, this is…
Since 2004, over 20 new proton beam centers, a type of radiation primarily identified as being effective in treating pediatric…
Radiation therapy is well established as one of the three primary approaches to treating cancer; however, it comes with a…
CAR-T cell therapy is an innovative new strategy that may revolutionize lymphoma treatment. Speaking from the 2017 National Cancer Research…
New studies are constantly evolving the field of lymphoma research, with trials continuously striving to find more effective treatments. At…
As the roles of various proteins within the human body become clearer, novel research can develop to produce effective therapies…
To efficiently produce effective therapies, it is necessary for experts within different specialties to collaborate. At the International Conference on…
Immunotherapy has emerged in recent years as a promising lymphoma treatment, with exciting new drug classes being developed with innovative…
As the finer details of how therapies interact within the body become clear, novel research to create more effective medications…
To produce safe and effective therapies for patients, novel research must first occur in cell culture systems. In this interview,…
There are two well-known checkpoint inhibitors that have shown efficacy in relapses/refractory Hodgkin lymphoma, nivolumab and pembrolizumab, both PD-1 inhibitors.…
Francine Foss, MD, from the Yale University School of Medicine, New Haven, CT, discusses targeting chemokines at the International Workshop…
“Both targeted agents, such as brentuximab vedotin, and checkpoint inhibitors, such as pembrolizumab, have shown activity in a subset of…
Dr. Jack West addresses the question of whether the data with various PD-1 and PD-L1 inhibitors in lung cancer management…
Patients who are actively engaged with their diagnosis, treatment and symptoms now have an outlet to share their treatment journey…
Neeraj Agarwal, MD Associate Professor of Medicine Director, Genitourinary Oncology Co-leader, Urologic Oncology Multidisciplinary Program Huntsman Cancer Institute, University of…
Pavlos Msaouel MD, PhD Chief Fellow, Hematology/Oncology MD Anderson Cancer Center discusses Renal Medullary Carcinoma at the 2017 Kidney Cancer…
MOASC Educational Series 2017 roundtable discussion on oncology billing and the new challenges.
Remy Turner presents the options available to providers to follow-up on claims that have been submitted for payment. Timeliness and…
Dawn Holcombe, MBA, FACMPE, ACHE DGH Consulting discusses Pharmacy Standards in transition and real at the MOASC Educational Series 2017
Elaine L. Towle, CMPE discusses MACRA and MIPS and an Oncology Billing Update: And Whats new for 2018? from the…
Dr. Jack West reviews the implications of the PACIFIC trial that establishes a role for durvalumab immunotherapy in stage III…
Christopher Wood, MD, Elizabeth Plimack, MD, Martin Voss, MD, Viraj Masters, MD, A. Ari Hakimi, MD consult on a several…
Brian Shuch, MD Assistant Professor of Urology and Radiology Yale School of Medicine Genomic Heterogeneity and the Small Renal Mass…
Martin Voss, MD Memorial Sloan Kettering discusses Integrated Biomarker Analysis for 412 RCC patients Treated on the Phase 3 COMPARZ…
Sumanta Kumar Pal, M.D City of Hope Cancer Center discusses IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized…
Comparative Genomic Profiling of Matched Maria Becerra, MD discusses Primary and Metastatic Tumors in Renal Cell Carcinoma at the 2017 Kidney Cancer Association…
Vadim S. Koshkin, MD Cleveland Clinic Taussig Cancer discusses Clinical Activity of Nivolumab in Patients with Non-Clear Cell Renal Cell…
Christopher G. Wood, M. D., FACS Professor and Deputy Chairman Douglas E. Johnson, M. D. Endowed Professorship In Urology Department…
Ronald M. Bukowski, MD discusses Training Medical Oncologists to be Experts in RCC at the 2017 Kidney Cancer Association symposium…
Martin Voss, MD Genitourinary Oncology Service Memorial Sloan Kettering Cancer Center, New York gives an Update on Genomic Classifiers in…
Joshua M. Lang, MD University of Wisconsin School of Medicine and Public Health discusses Circulating Biomarkers in Clear Cell Renal…
Payal Kapur, M.D. Associate Professor of Pathology and Urology, UTSW Group Leader Genitourinary Pathology, UTSW Kidney Cancer Program co-leader, Simmons…
Leigh Ellis Ph.D. Assistant Professor Department of Oncologic Pathology Dana-Farber Cancer Institute Brigham and Womens Hospital Harvard Medical School discusses…
Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery Affiliate Member Department of Computational Biology discusses Cell line and…
Viraj A. Master of Emory University discusses Neoadjuvant Presurgical Therapy for RCC: Lessons Learned at the 2017 Kidney Cancer Association…
Tim Eisen University of Cambridge discusses Perspective(s) on Adjuvant Trials at the 2017 Kidney Cancer Association symposium in Miami, FL.
Grant D Stewart BSc, MBChB, FRCSEd (Urol), PhD University Lecturer and Consultant in Urological Surgery, Academic Urology Group, University of…
Axel Bex, MD, PhD The Netherlands Cancer Institute Amsterdam, The Netherlands outlines the Challenges in SURTIME and CARMENA at the…
Mark W. Ball, MD Staff Clinician | Assistant Research Physician Urologic Oncology Branch National Cancer Institute National Institutes of Health…
Steven C. Campbell, MD, PhD Program Director, Vice Chairman Department of Urology Center for Urologic Oncology Glickman Urological and Kidney…
Rodolfo Borges dos Reis MD; PhD. Head of Uro-oncology Ribeirão Preto Medical School The University of São Paulo answers teh…
R. Houston Thompson, MD Professor of Urology Mayo Clinic, Rochester, MN @HThompsonMD presents Guidelines on Managing SRMs: Compare and Contrast…
John T. Leppert, MD MS Associate Professor, Stanford University Director of Urologic Oncology, VA Palo Alto @johnleppert presents Nephrometry: 21st…
Loren Tarantino, MS SMP Global Partner discusses Systems Thinking Approach to Strategic Management at the MOASC educational series on November…
Roberta Buell Principal, On Point Oncology presents the Revenue Cycle State of the State: Where are we? How can we…
Elaine L. Towle, CMPE Division Director, Analysis & Consulting Services Clinical Affairs provides an in-depth look at the MACRA Quality…
Merrianne Do, Pharm D of Walgreen’s discusses it’s new pilot program for specialty oncology drugs at the MOASC educational series…
Andrew W. Hahn, MD University of Utah Huntsman Cancer Institute @onchahn discusses Predictive genomic markers of response to VEGF targeted…
IRINA PROSKOROVSKY, MSC discusses Axitinib and Cabozantinib in the Treatment of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma (mRCC): Results…
Laurence Albiges, MD, PhD Institut Gustave Roussy Villejuif, France gives an overview of TiNivo A Phase Ib Dose Escalation Trial…
Michael Roger Harrison, MD of Duke University presents Deferred Systemic Therapy (DST) for Metastatic Renal Cell Carcinoma: Preliminary Prospective Experience…
ALEXANDRA DRAKAKI, MD, PHD UNIVERSITY OF CALIFORNIA LOS ANGELES gives an overview of A Phase I, Open Label, Dose Escalation…
Martin H. Voss, MD of Memorial Sloan Kettering outlines the DART Study: A phase 2 randomized trial of dalantercept plus…
Paulo G. Bergerot, MD of City of Hope Comprehensive Cancer Center discusses Variations in treatment patterns for metastatic renal cell…
Cristiane Decat Bergerot, Phd answers the question How should we deal with the psychological burden of mRCC? at the 2017…
Bernard Escudier, Gustave Roussy, Villejuif, FRANCE answers the question How should we treat brain metastases from RCC? at the 2017…
Hans Hammers MD, PhD UT Southwestern asks the question How should we Incorporate Radiotherapy in RCC Management? at the 2017…
James Brugarolas, M.D., Ph.D. Chair, CDMRP Kidney Cancer Research Program Programmatic Panel discusses the CDMRP Kidney Cancer Research Program at…
Igor Kuzmin, Ph.D. Translational Research Program (TRP) DCTD, NCI trp.cancer.gov asks the question Applying for a SPORE Grant: How to…
Tian Zhang, MD Assistant Professor of Medicine Duke Cancer Institute discusses VEGF TKI/immunotherapy combinations will become the standard of care…
Bradley A McGregor, MD Clinical Director Lank Center for Genitourinary Oncology Dana Farber Cancer Institute discusses TKI Monotherapy Still has…
Brian I. Rini, M.D. Department of Solid Tumor Oncology Cleveland Clinic Taussig Cancer Center highlights Ipi / Nivo is the…
Jianjun Gao, MD, PhD Assistant Professor Genitourinary Medical Oncology of MD Anderson outlines a Discussion of Correlatives Associated with Presurgical…
Lauren C. Harshman, MD discusses EA8143 PROSPER RCC: The Potential For Discovery through Correlatives at the 2017 Kidney Cancer Association…
Brian Shuch, MD of the Yale School of Medicine discusses the Biomarker Analysis of MET Alterations and Papillary Subtype in…
Mark Larkin, Director, Vitaccess gives an overview of the Kidney Cancer Association Digital Registry at the 2017 Kidney Cancer Association…
Laurence Albiges of Gustave Roussy, Villejuif, France discusses Non clear cell RCC Bridging Translational Data to the clinic Papillary RCC…
Gabriel Malouf, MD of Pitié-Salpêtrière Hospital University Pierre and Marie Curie discusses Collecting Duct Carcinomas at the 2017 Kidney Cancer…
James J. Hsieh MD of Siteman Cancer Center, Washington University discusses how to classify the unclassified renal cell carcinoma at…
Gilberto de Lima Lopes, MD discusses the Impact of Geographic Distribution on Outcome in Cancer Africa & Asia at the…
André P. Fay, MD, PhD, Professor, PUCRS School of Medicine Chief, Medical Oncology Department – Hospital São Lucas da PUCRS…
Raje, Noopur MD of the Massachusetts General Hospital Cancer Center highlights that denosumab now gives clinicians more choices for treating…
Raje, Noopur MD of the Massachusetts General Hospital Cancer Center discusses the next steps for Denosumab at the Lymphoma-Myeloma 2017…
Raje, Noopur S., MD from Massachusetts General Hospital Cancer Center asks the question is it possible to switch from one…
Raje, Noopur, MD of Massachusetts General Hospital Cancer Center discusses if it is possible to switch from one bone targeting…
Robert G. Uzzo, MD of Fox Chase Cancer Center presents his thoughts on the Cost Effectiveness in Renal Cell Carcinoma…
Noopur Raje, MD of Massachusetts General Hospital Cancer Center outlines how the recently released economic analysis of Denosumab v. Zoledronic…
John L. Gore, MD, MS from the University of Washington discusses Quality Measures in Renal Cell Carcinoma at the Kidney…
Maxine Sun, PhD, MPH of Dana-Farber Cancer Institute discusses the Utility Pitfalls and Perils of Using Secondary Data for RCC…
Noopur Raje, MD of Massachusetts General Hospital Cancer Center discusses her findings in which Denosumab is favored in newly diagnosed…
Nizar M. Tannir, MD Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson…
Walter Stadler, MD of The University of Chicago discusses the Correlatives Associated with Bevacizumab/Atezolizumab at the annual 2017 Kidney Cancer…
Andrew Fabiano, MD, is the Director of the Spinal Oncology Center at Roswell Park Cancer Institute. He shares with fellow…
Ronald Alberico, MD, Director, Neuroradiology/Head & Neck at Roswell Park Cancer Institute presents for fellow physicians on identifying patients who…
What is next-generation sequencing and what is its annotation process? Carl Morrison, MD, DVM, Executive Director of the Center for…
Khurshid Guru, MD, Chair, Department of Urology and Director, Robotic Surgery at Roswell Park Cancer Institute offers advice for physicians…
Gurkamal Chatta, MD, Clinical Chief of Genitourinary Medicine, presents on immuno-oncology, new immunotherapy cancer treatments and how the immune system…
Drs. Kunle Odunsi and Richard Koya provide details on a first-of-its-kind cancer immunotherapy clinical trial, available only at Roswell Park.This…
Dr. Jack West reviews the key differences between findings that are worthy of clinical research and those that should be…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Ji?Ã Schwarz discusses challenges in…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Andreas Reiter discusses the biology…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Jean Luc Villeval discusses the…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Radek C. Skoda discusses new…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Astrid Olsnes Kittang discusses the…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Carmen Aanei elucidates recent advances…
Dr. Jack West reviews evidence that a subset of patients with advanced NSCLC demonstrate “hyper-progressing disease” (HPD), worsening cancer at…
With the knowledge clinicians are gaining about the driver mutations of myeloproliferative neoplasms (MPNs), JAK inhibitors have become more recognized…
Interested in learning more about developing options to treat myeloproliferative neoplasms (MPNs)? Treating MPNs isnt a one-size-fits-all approach, and research…
Ludovic Bourre, Director of Scientific Engagement for Crown Bio Science gives a quick outline on why he feels T cell…
Anti-OX40 has been demonstrated to improve tumor free survival in mice and is now moving past the first Phase 1…
Ludovic Bourre, Director of Scientific Engagement for Crown Bio Science gives an overview of the Phase 1 Study of Anti-OX40…
Dr. Jack West reviews new findings highlighting the utility of using the biomarker tumor mutation burden (TMB) to predict which…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Alessandro M. Vannucchi discusses the…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Srdan Verstovsek discusses therapeutic insights…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Claire Harrison outlines her approach…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Hans Michael Kvasnicka discsuses myelofibrosis…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Jaroslav Cermak discusses new opportunities…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Aristoteles Giagounidis discusses the optimal…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Norbert Gattermann discusses iron chelation…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Eva Hellström-Lindberg outlines her approach…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Austin G. Kulasekararaj discusses the…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Martin Griesshammer outlines his view…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that circulating tumor…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher L. Hallemeier argues that observation…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Julio Garcia-Aguilar argues that observation without…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Scott Kopetz discusses the difference in…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that immunotherapy is…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eric Van Cutsem argues that TAS-102…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eric Van Cutsem argues that EGFR…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that either bevacizumab…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jonathan Strosberg provides an update in…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Scott Kopetz provides an update to…
Dr. Aly-Khan Lalani, MD highlights a study he presented at ESMO 2017 about the usefulness Neutrophil-to-lymphocyte ratio (NLR) and how…
Dr. Aly-Khan Lalani, MD gives an overview of the advancements in Kidney Cancer presented at ESMO 2017 including the Cabosun…
Dr. Aly-Khan A. Lalani, MD discusses the impact of Neutrophil-to-lymphocyte ratio (NLR) in mRCC and it’s effect on outcomes. BACKGROUND:…
During this segment from the Living Well series, Dr. Bart Scott, breaks down whats occurring at a cellular level with…
Although essential thrombocythemia (ET) is generally thought of as a disease that only affects the middle age and elderly population,…
The approvals of palbociclib and ribociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, provided advanced or metastatic hormone-positive,…
In this Velocity Vlog activity, Dr. Howard L. Kaufman of the Rutgers Cancer Institute contextualizes updates to the standard of…
In this Velocity Vlog activity, Dr. Paul Nghiem of the University of Washington shares emerging data and expert analysis about…
The approvals of palbociclib and ribociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, provided advanced or metastatic hormone-positive,…
Dr. Jack West reviews new evidence providing long-needed guidance on what patient surveillance after potentially curative surgery for early lung…
Dr. Jack West assesses the merits of a combination of chemotherapy with pembrolizumab (Keytruda) based on the evolving efficacy data,…
How do you know if your MPN is progressing? Will it show in your blood work or will symptoms increase?…
Scott S. Tykodi MD of Seattle Cancer Care Alliance notes that the data from Checkmate 214 is clear that overall…
Michael Needle, MD and Chief Medical Officer for AVEO Oncology gives an update for the Phase 3 TIVO-3 trial, a…
Scott S. Tykodi, MD of Seattle Cancer Care Alliance discusses the recently released Checkmate 214 data and how favorable RCC…
Michael N. Needle, MD, and Chief Medical Officer of AVEO Oncology goes over the TIVO-1 Trial results first released in…
Dr. Scott S. Tykodi, MD reveals the results of the Checkmate – 214 trial with combined immunotherapy nivolumab plus ipilimumab…
Michael Needle, MD and Chief Medical Officer of AVEO Oncology goes over why and how Tivozanib (FOTIVDA(R)) was given approval…
K. Robert Shen, MD of of the Mayo Clinic in Rochester, MN discusses what to do with an esophageal cancer…
Patients often struggle with the decision to seek an opinion elsewhere. Is your own doctors opinion enough? Will you offend…
Dr. Jack West reviews the important, clinically relevant results of the CheckMate-153 trial that asks whether there is a value…
Dr. Jack West summarizes the likely practice-changing results of the FLAURA trial of osimertinib vs. standard of care EGFR TKI…
Dr. Jack West reviews data from ESMO 2017 & the NEJM paper on the PACIFIC trial of durvalumab vs. placebo…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. David H. Ilson argues that peri-operative…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jonathan Strosberg argues that there is…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Michael A. Choti argues that there…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Zsofia K. Stadler assesses the state…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Scott Kopetz provides an update on…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that the…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Neil H. Segal provides an update…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Zsofia K. Stadler provides an update…
Dr. Jack West explains the potential value PD-L1 expression during the initial workup of patients with advanced NSCLC, in the…
Held on 29 June 2017 in Barcelona, Spain, the Optimizing the Continuum of Care for Patients with Pancreatic Cancer symposium…
Dr. Jack West reviews data from pivotal trials showing that platforms that enable better communication between the cancer patient and…
K. Robert Shen, MD, of the Mayo Clinic in Rochester, MN discusses how a new study highlights how estrogen could…
Professor Gareth Thomas at the University of Southampton, United Kingdom discusses the next steps for the preclinical models of GKT831
Hagop M. Kantarjian, MD of MD Anderson Cancer Center goes over some possible next steps for Inotuzumab after it has…
Hagop M. Kantarjian, MD of MD Anderson Cancer Center discusses how veno occlusive disease may cause complications while using inotuzumab…
Hagop M. Kantarjian, MD of MD Anderson Cancer Center states “We are witnessing a slow motion revolution in ALL” talking…
Professor Gareth Thomas at the University of Southampton, United Kingdom discusses the relatively well tolerated GKT831 in other disease states.
K. Robert Shen, MD of Mayo Clinic in Rochester reports that female patients with locally advanced esophageal cancer that is…
Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia says now that Besponsa or Inotuzumab is FDA…
Professor Gareth Thomas at the University of Southampton, United Kingdom discusses his preclinical research about cancer associated fibroblasts (CAFs) and…
Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia states the median survival rate nearly doubles combining…
Professor Gareth Thomas of University of Southampton discusses data in multiple preclinical models that showed GKT831 efficiently targeted cancer associated…
Dr. Jack West reviews the promise of combinations of immunotherapies for advanced NSCLC and the implications for the field of…
Dr. Jack West discusses the implications of a positive FLAURA trial, which revealed a significant improvement in progression-free survival for…
Dr. Jack West reviews the potential new role for immunotherapy in locally advanced NSCLC based on the early report that…
Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia gives the trial overview and conclusions of Pfizer’s…
In this presentation from the Treatment Dilemmas in Polycythemia Vera: Leveraging Evidence and Clinical Experience to Improve Patient Care symposium,…
In this presentation from the Treatment Dilemmas in Polycythemia Vera: Leveraging Evidence and Clinical Experience to Improve Patient Care symposium,…
In this presentation from the Treatment Dilemmas in Polycythemia Vera: Leveraging Evidence and Clinical Experience to Improve Patient Care symposium,…
In this discussion, recorded during the 2017 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 4-5, 2017 in…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that there…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Ghassan Abou-Alfa argues that regorafenib should…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Mark A, Schattner provides an update…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eileen O’Reilly provides an update in…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that gemcitabine/capecitabine…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jordan Berlin argues that gemcitabine/nab-paclitaxel is…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher H. Crane argues that preoperative…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jordan Berlin argues that chemotherapy alone…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher L. Hallemeier argues that surgery…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher H. Crane argues that post-operative…
At a recent town meeting in partnership with Robert H. Lurie Comprehensive Cancer Center in Chicago, Dr. Brady Stein helps…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Ghassan Abou-Alfa provides an update in…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Umberto Ricardi discusses the use of loco-regional…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Suresh Senan discusses new radiotherapy techniques for…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Jesus Corral discusses how best to manage…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Joachim G. Aerts discusses the utilization of…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Sandrine Aspeslagh elucidates the basis for immunotherapy in…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Paul Van Schil arguest that trimodality therapy…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Ugo Pastorino discusses primary and secondary prevention of…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Stefano Gasparini discusses how best to use…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Ramon Rami-Porta discusses updates on the TNM…
Jeffrey E. Lancet, MD of Moffitt Cancer Center discusses the next steps and future development for vyxeos in AML, which…
Jeffrey E. Lancet, MD of Moffitt Cancer Center gives an overview of a phase 3 randomized trial, which focused on…
Jeffrey E. Lancet, MD of Moffitt Cancer Center discusses the impact of vyxeos on future clinical practice.
Jeffrey E. Lancet, MD of Moffitt Cancer Center discusses common questions hes been asked regarding the safety and efficacy of…
Karen Smith, MD outlines the safety and efficacy of Vyxeos the newly approved chemotherapy for the treatment of adults with…
Karen Smith answers some common questions and concerns about the newly FDA approved Vyxeos for the treatment of adults with…
The U.S. Food and Drug Administration (FDA) has approved VyxeosTM (daunorubicin and cytarabine) liposome for injection for the treatment of…
Dr. Catriona Jamieson, from Moores Cancer Center at UC San Diego Health, joined Patient Power to discuss considerations when choosing…
Dr. Alex Spira, Director of the Virginia Cancer Specialist Research Institute and ASCO President Dr. Bruce Johnson, discuss research around…
Daniela Bota, MD of UC Irvine Health discusses the use of neratinib and capecitabine in patients with breast cancer brain…
Daniela Bota, MD of UC Irvine Health discusses the results of nivolumab versus nivolumab plus ipilimumab in patients with Melanoma…